SCHEMBL1891741

SCHEMBL1891741

[CH2][C@H](CNC(=O)OC(C)OC(=O)C(C)C)c1ccc(Cl)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
L3MBTL1 Q9Y468 3/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 1/20 0.37
UTS2R Q9UKP6 1/20 0.37
RAB9A P51151 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ALDH1A1 P00352 2/20 0.35
FFAR2 O15552 1/20 0.35
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2A Q12879 1/20 0.34
GRIN2B Q13224 1/20 0.34
GRIN2C Q14957 1/20 0.34
GRIN3A Q8TCU5 1/20 0.34
CYP2C9 P11712 3/20 0.33
CYP2C19 P33261 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1884906 1.00 MAPT (0.42) MAPTL3MBTL1HPGDHSD17B10UTS2R
SCHEMBL1884778 0.89 MAPT (0.41) MAPTL3MBTL1HPGDHSD17B10UTS2R
SCHEMBL1886204 0.89 MAPT (0.41) MAPTL3MBTL1HPGDHSD17B10UTS2R
SCHEMBL1888802 0.89 MAPT (0.41) MAPTL3MBTL1HPGDHSD17B10UTS2R
SCHEMBL1884992 0.89 MAPT (0.41) MAPTL3MBTL1HPGDHSD17B10UTS2R
SCHEMBL1890710 0.85 MAPT (0.41) MAPTL3MBTL1HPGDHSD17B10UTS2R
SCHEMBL1886106 0.85 MAPT (0.41) MAPTL3MBTL1HPGDHSD17B10UTS2R
SCHEMBL1884726 0.84 MAPT (0.40) MAPTL3MBTL1HPGDHSD17B10UTS2R
SCHEMBL1884773 0.84 MAPT (0.40) MAPTL3MBTL1HPGDHSD17B10UTS2R
SCHEMBL1885017 0.83 MAPT (0.40) MAPTL3MBTL1HPGDHSD17B10RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935686-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. (US) 2011-05-03 US disclosed
US-20090124582-A1 Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use XENOPORT, INC. (US) 2009-05-14 US disclosed
US-7494985-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. (US) 2009-02-24 US disclosed
US-20060111325-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. 2006-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111325-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use APEH, AASDHPPT, AGPS MAPT 4107/4885L3MBTL1 2410/4885HPGD 1458/4885
US-20090124582-A1 Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use APEH, AASDHPPT, AGPS MAPT 4107/4885L3MBTL1 2410/4885HPGD 1458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.